Ermium Therapeutics SAS

https://www.ermium.com

Ermium Therapeutics was founded in June 2019 by Jean-Philippe Herbeuval, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo. In addition, Ermium Therapeutics won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education. *

	Start	2019-06-28 established
	Industry	CXCR4 agonist
	Industry 2	drug development
	Person	Crouzet, Joël (Ermium Therapeutics 201909 CEO)

	Region	Paris
	Country	France
	Street	16 Boulevard Saint Germain
	City	75005 Paris
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Domain Therapeutics S.A.. (9/11/19). "Press Release: Domain Therapeutics Invests in Ermium Therapeutics to Develop First-in-class CXCR4 Candidate for Autoimmune Diseases". Strasbourg.

		Record changed: 2024-03-30

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Ermium Therapeutics SAS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)